How do PCSK9 Inhibitors compare with other lipid-lowering therapies from a toxicological perspective?
From a toxicological perspective, PCSK9 inhibitors are considered to have a favorable profile compared to traditional therapies like statins, which can cause muscle-related side effects and liver enzyme elevations. Despite their efficacy, the novel mechanism and lack of hepatic metabolism of PCSK9 inhibitors contribute to their reduced toxicological burden.
